Evidence map›Paper›PMID 39076851›Full record

ArticleFrontiers in sports and active living2024

5'-UMP inhibited muscle atrophy due to detraining: a randomized, double-blinded, placebo-controlled, parallel-group comparative study.

Mika Inoue, Atsushi Kubota, Yuji Takazawa, Kosuke Nakagawara, Kazuya Ishige, Yoshio Suzuki

Abstract read
In one paragraph

Article in Frontiers in sports and active living, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mika Inoue *Juntendo Administration for Sports, Health and Medical Sciences, Juntendo University, Tokyo, Japan.
Atsushi Kubota *Graduate School of Health and Sports Science, Juntendo University, Chiba, Japan.
Yuji TakazawaGraduate School of Health and Sports Science, Juntendo University, Chiba, Japan.
Kosuke NakagawaraBiochemicals Division, YAMASA Corporation, Chiba, Japan.
Kazuya IshigeBiochemicals Division, YAMASA Corporation, Chiba, Japan.
Yoshio SuzukiGraduate School of Health and Sports Science, Juntendo University, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: A short period of disuse of 1-2 weeks due to factors such as illness or injury can lead to muscle atrophy, affecting both athletic performance and health. Recent research has shown that uridine 5'-monophosphate (5'-UMP) can counteract disuse-induced muscle atrophy by increasing PGC-1α expression and inhibiting atrogin-1 expression. However, the effect of 5'-UMP on disuse muscle atrophy in humans remains unknown. Therefore, the aimed of this study was to explore the effects of 5'-UMP supplementation during detraining on short-term disuse muscle atrophy in healthy men. Methods: Following a 6-week resistance training program on upper arm, healthy men were randomized to either a UMP group ( Results: Both groups showed a significant decrease in muscle thickness at MT70. The relative decrease was greater in the placebo group (2.4 ± 2.8%) than in the UMP group (0.0 ± 2.0%), significantly ( Conclusion: After the hypertrophy, 5'-UMP may prevent muscle atrophy due to the detraining within the first week.

Indexed as

muscle thicknessresistance trainingsarcopeniaUMPuridine 5′-monophosphate

Identifiers

PMID39076851
PMCPMC11284071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.